Caricamento...
Gilteritinib Plus Azacitidine Combination Shows Promise in Newly Diagnosed FLT3‐Mutated AML
New data from the phase III LACEWING trial support the safety and feasibility of combining gilteritinib with azacitidine in patients with newly diagnosed FLT3‐mutated acute myeloid leukemia who are not eligible for induction therapy, suggesting an important new treatment approach for these patients....
Salvato in:
| Pubblicato in: | Oncologist |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley & Sons, Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7869119/ https://ncbi.nlm.nih.gov/pubmed/33368797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13652 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|